/Merck%20%26%20Co%20Inc%20HQ%20-by%20Sundry%20Photography%20via%20iStock.jpg)
Valued at a market cap of $191.3 billion, Merck & Co., Inc. (MRK) is a healthcare company that offers human health pharmaceuticals for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes. The Rahway, New Jersey-based company also operates an animal health division, providing veterinary pharmaceuticals, vaccines, and services.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and MRK fits the label perfectly, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company benefits from its strong research and development capabilities, a robust oncology portfolio, led by its top-selling cancer drug Keytruda, and its diversified business model that includes both human and animal health segments. It is a global leader in immuno-oncology and continues to expand its pipeline through innovation and strategic collaborations.
